You are here

  • Home
  • Archive
  • Volume 12, Issue 8
  • Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab

Citation Tools

Article menu
Case report
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Cavalcante L, Chandana S, Lakhani N, et al
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab
Journal for ImmunoTherapy of Cancer 2024;12:e009475. doi: 10.1136/jitc-2024-009475